Skip to Main Content

HLHRUXO: Ruxolitinib Therapy for HLH

About this study

This study will test a new drug therapy for hemophagocytic lymphohistiocytosis . This condition is also known as HLH or HLH disease.

The drug in this study is called ruxolitinib (Jakafi). The U.S. Food and Drug Administration (FDA) has approved ruxolitinib to treat adults with certain blood disorders. The FDA has also approved the drug to treat a condition called steroid refractory graft-versus-host disease in adults and children at least 12 years old.

Research suggests ruxolitinib may reduce the immune system inflammation that happens with HLH. Studies also suggest ruxolitinib may work better than other HLH therapies.

Although studies have found that ruxolitinib is safe in children with cancer, we do not know the safest and best dose of this drug in children with HLH. This study will only use doses of ruxolitinib that have been shown to be safe when given to children with cancer.

Eligibility overview

  • 6 weeks to 22 years old
  • Newly diagnosed HLH
  • History of HLH unresponsive to prior therapy

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.


Full title:

Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

Study goal:

This main goal of this study is to find out if ruxolitinib will improve the survival rate for children with HLH.


6 weeks to 22 years old

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.


Learn more